PRE-CONFERENCE WORKSHOPS

Oral therapies are standard of care across a range of cancers. These therapies are effective at controlling disease but often have unique adverse event profiles which create tolerability issues often early in the treatment course. Early detection and management of adverse events is critical to ensuring patient adherence and maximising the full benefit from the treatment. Nurses and allied health have routine interactions with patients receiving oral therpaies are therefore well placed to detect and discuss adverse events and recommend alterations to treatment plans, to enable patients to remain on therapy.  The proposed workshop session is designed to improve nurse and allied health professionals confidence in the detection of unique adverse events, by reviewing adverse event profiles of common oral therapies, and providing practical guidance on identifying these events and recommending and communicating appropriate interventions. Content will be developed independently by the selected experts.

• Review the special adverse event profiles of common oral anti-cancer therapies

• Provide guidance on how to identify and discuss adverse events with patients and carers

• Review case examples with an opportunity for discussion and feedback

This workshop will be group-based with an opportunity for interactive discussion and practical guidance

• Meredith Cummins, CEO, NeuroEndocrine Cancer Australia, NSW

• Gail Rowan, Senior Pharmacist, Peter MacCallum Cancer Centre, VIC

• Cassandra Mazza, Nurse Practitioner, Sunshine Coast University Hospital, QLD

• Melanie Rabbets, Nurse Practitioner, Blacktown Cancer and Haematology Centre, NSW

• Add to your registration - $155 AUD

• Workshop only - $350 AUD